Brain MRI Surveillance Alone Helps Preserve Cognition in Small Cell Lung Cancer

A recent study presented at the IASLC 2026 World Conference on Lung Cancer has found that regular brain MRI surveillance without prophylactic cranial irradiation can lead to better cognitive outcomes in patients with small-cell lung cancer (SCLC), without negatively impacting overall survival. The SWOG S1827 MAVERICK Phase III randomized trial, led by Dr. Chad Rusthoven of the University of Colorado, involved 304 patients with limited or extensive-stage SCLC who had no brain metastases at the start of the study.

Participants were randomly assigned to receive MRI surveillance alone or MRI surveillance combined with prophylactic cranial irradiation (PCI). Brain MRIs were conducted every three months during the first year and every six months during the second year, with cognitive assessments administered at the same intervals. The results showed that patients in the MRI-only group had a significantly better cognitive failure-free survival (hazard ratio of 0.60) compared to those who received MRI and PCI.

This advantage was consistent across both limited and extensive-stage SCLC patients and was not influenced by immunotherapy use. While the study found no significant difference in overall survival or progression-free survival, the findings support MRI surveillance as the standard of care for SCLC patients, as it appears to improve cognitive function without compromising other outcomes.